Business
Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress
LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will present an updated data analysis from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, taking place from October 17-21, 2025. AVA6000 is a peptide drug conjugate consisting of doxorubicin conjugated with a
About this update from Avacta Group Plc
[{"type":"image","alt":"AVACTA GROUP PLC","displaySize":"","headline":null,"caption":"AVACTA GROUP PLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":109,"url":"https://media.zenfs.com/en/globenewswire.com/2179b51c1f91cddf1addee3cc0dee04b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BuJbdPFE1KPW3OqbkUSHWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2179b51c1f91cddf1addee3cc0dee04b","width":300,"height":109}},"lazy":false},{"type":"text","content":"LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will present an updated data analysis from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, taking place from October 17-21, 2025. AVA6000 is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment.","length":582,"tagName":"p"},{"type":"text","content":"The poster presentation will be based on the most recent data analysis from the Phase 1a trial of FAP-Dox (AVA6000) in patients with Fibroblast Activation Protein (FAP)-positive solid tumors. Avacta completed the Phase 1a enrollment dose escalation portion of the clinical trial in late 2024, with patient enrollment ongoing in multiple dose expansion cohorts of a Phase 1b study.","length":380,"tagName":"p"},{"type":"text","content":"Abstract details are listed below and available online on the ESMO website.","length":75,"tagName":"p"},{"type":"text","content":"Avacta will hold an investor event shortly after the ESMO presentation. Further details will be made available nearer the time.","length":127,"tagName":"p"},{"type":"text","content":"Title: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumorsSession Title: Developmental TherapeuticsSession Date and Time: 17 October, 19:40 - 20:00Location: Berlin Auditorium - Hub 27Abstract Presentation Number: 964PSpeaker: William D. Tap","length":398,"tagName":"p"},{"type":"text","content":"For furthe...